MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

• click to rate

  Posted by Two Blokes Jul 11 - Filed in Stock - 9 views
  
  Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.